What is unique about betaxolol 0.5% and 0.25%?

• A. Nonselective beta blocker
• B. No respiratory side effects
• C. Prostaglandin analog
• D. Selective for beta-1, minimizing respiratory side effects

Answer: (D)

Betaxolol is a cardioselective beta-adrenergic blocker used to lower intraocular pressure in glaucoma. What makes its 0.5% and 0.25% formulations notable is that it preferentially blocks beta-1 receptors, which are mostly in the heart, with relatively less effect on beta-2 receptors in the lungs. This beta-1 selectivity means it has a lower risk of causing bronchospasm or other respiratory side effects compared with nonselective beta blockers that block both beta-1 and beta-2 receptors. While not entirely free of respiratory effects, its selectivity tends to minimize those risks, making it a safer choice for patients with respiratory sensitivity. It is not a prostaglandin analog, and the key distinction here is the beta-1 selectivity that reduces pulmonary impact.